1
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
Condition(s):Glioma, Malignant; Gliosarcoma; Astrocytoma of BrainLast Updated:September 17, 2019Not yet recruiting
Temozolomide: 992 Clinical Trials, Page 1 of 100
Hide Studies Not Open or Pending
2
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression
Condition(s):Adult Brainstem GliomaLast Updated:August 21, 2019Recruiting
3
5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme
Condition(s):Glioblastoma MultiformeLast Updated:February 17, 2021Completed
4
Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
Condition(s):Extensive Stage Small Cell Lung CancerLast Updated:November 23, 2016Unknown status
5
Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
Condition(s):Anaplastic Oligodendroglioma; Anaplastic OligoastrocytomaLast Updated:April 26, 2016Completed
6
Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
Condition(s):Glioma; GlioblastomaLast Updated:October 8, 2020Recruiting
7
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
Condition(s):Neuroendocrine CarcinomasLast Updated:October 26, 2020Completed
8
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
Condition(s):Glioblastoma; Brain TumorLast Updated:February 1, 2021Not yet recruiting
9
Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17)
Condition(s):GlioblastomaLast Updated:February 12, 2020Recruiting
10
HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Condition(s):MelanomaLast Updated:February 19, 2018Unknown status